Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial

The Lancet Diabetes & Endocrinology 2026

View at publisher

Authors: Linong Ji, Malik Benamar, Viswanathan Mohan, Laura Pletsch-Borba, Francesca Porcellati, Ni Wang, Hirotaka Watada, Rosangela Roginski Rea

DOI: 10.1016/s2213-8587(26)00136-1

Cited by: 1

References: 17

Fields of Study & Subjects

Diabetes and associated disorders Natural Antidiabetic Agents Studies Dermatology and Skin Diseases

References 17